Short-Term Effects of Brolucizumab in the Treatment of Wet Age-Related Macular Degeneration or Polypoidal Choroidopathy Refractory to Previous Anti-Vascular Endothelial Growth Factor Therapy

Short-Term Effects of Brolucizumab in the Treatment of Wet Age-Related Macular Degeneration or Polypoidal Choroidopathy Refractory to Previous Anti-Vascular Endothelial Growth Factor Therapy

<i>Background and objectives</i>: To report the initial response to a single intravitreal brolucizumab (IVI-B) injection in wet age-related macular degeneration (wAMD) or polypoidal choroidopathy (PCV) complicated with either persistent subretinal fluid (SRF) or pigment epithelial detach...

Full description

Bibliographic Details
Main Authors: Alan Y. Hsu, Chih-Ying Lin, Chun-Ju Lin, Chun-Ting Lai, Ning-Yi Hsia, Jane-Ming Lin, Peng-Tai Tien, Ping-Ping Meng, Wei-Ning Ku, Wen-Lu Chen, Yi-Yu Tsai
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Medicina
Subjects:
anti-vascular endothelial growth factor therapy
brolucizumab
pigment epithelial detachment
polypoidal choroidopathy
subretinal fluid
wet age-related macular degeneration
Online Access:https://www.mdpi.com/1648-9144/58/12/1703

Internet

https://www.mdpi.com/1648-9144/58/12/1703

Similar Items